Vaxcyte Inc

For the period ended Dec 31, 2023. Filed Feb 27, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 27, 2024

PCVX$66.36-1.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity

(in thousands, except share data)

	Accumulated
Additional · Other · Total
Common Stock · Paid-in · Accumulated · Comprehensive · Stockholders’
Shares · Amount · Capital · Deficit · Income (Loss) · Equity
Balance — December 31, 2020	51,071,593		$54		$544,353			$(198,564)		$—		$345,843
Exercise of stock options	931,114		—		3,012			—		—		3,012
Issuance of common stock to Lonza Ltd.	399,680		1		10,000			—		—		10,001
Issuance of common stock in connection with at-the market offering, net of issuance costs of $479	567,045		1		13,846			—		—		13,847
Issuance of common stock under Employee Stock Purchase Plan	62,546		—		888			—		—		888
Vesting of early exercised stock options	—		—		16			—		—		16
Stock-based compensation expense	—		—		10,729			—		—		10,729
Unrealized losses on investment	—		—		—			—		(241)		(241)
Net loss	—		—		—			(100,077)		—		(100,077)
Balance — December 31, 2021	53,031,978		$56		$582,844			$(298,641)		$(241)		$284,018
Exercise of stock options	1,178,572		1		4,894			—		—		4,895
Issuance of common stock and pre-funded warrants in connection with public follow -on offerings, net of issuance costs of $45,814	21,062,500		21		759,160			—		—		759,181
Issuance of common stock in connection with at-the market offering, net of issuance costs of $3,107	3,921,528		4		97,295			—		—		97,299
Issuance of common stock for Sutro stock payment	167,780		—		7,995			—		—		7,995
Issuance of common stock under Employee Stock Purchase Plan	61,709		—		1,033			—		—		1,033
Release of restricted stock units	46,603		—		(861)			—		—		(861)
Vesting of early exercised stock options	—		—		8			—		—		8
Stock-based compensation expense	—		—		23,650			—		—		23,650
Unrealized losses on investment	—		—		—			—		(120)		(120)
Net loss	—		—		—			(223,485)		—		(223,485)
Balance — December 31, 2022	79,470,670		$82		$1,476,018			$(522,126)		$(361)		$953,613
Exercise of stock options	537,808		1		5,607			—		—		5,608
Issuance of common stock and pre-funded warrants in connection with public follow -on offerings, net of issuance costs of $29,952	13,030,000		13		545,289			—		—		545,302
Issuance of common stock in connection with at-the market offering, net of issuance costs of $2,237	2,095,943		2		90,739			—		—		90,741
Issuance of common stock under Employee Stock Purchase Plan	76,275		—		2,038			—		—		2,038
Release of restricted stock units	154,135		—		(3,876)			—		—		(3,876)
Vesting of early exercised stock options	—		—		8			—		—		8
Stock-based compensation expense		—		48,760			—		—		48,760
Unrealized gains on investment		—		—			—		538		538
Cumulative translation adjustment	—		—		—			—		2		2
Net loss						(402,266)				(402,266)
Balance — December 31, 2023	95,364,831		$98		$2,164,583			$(924,392)		$179		$1,240,468

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.